Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome

Gil Klinger*, Paul Merlob

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Depression is common in women of childbearing age and especially during pregnancy and the postpartum period. Selective serotonin reuptake inhibitors (SSRIs) are increasingly being used to treat depression prior to and throughout pregnancy. Up to 30% of the newborn infants exposed to SSRIs may present with clinical signs during the first days after birth. Neonatal abstinence syndrome (NAS) describes this clinical syndrome resulting from prior prolonged exposure to SSRI induced by cessation of the drug. NAS includes a wide spectrum from mild to severe non-specific symptoms which were categorized into four groups of effects: central nervous system (depression followed by excitation), gastrointestinal, autonomic and respiratory. A protocol for observation of SSRI-exposed newborns is presented including an objective method (Finnegan score) to monitor onset, progression and improvement of NAS symptoms.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalIsrael Journal of Psychiatry and Related Sciences
Issue number2
StatePublished - 2008


Dive into the research topics of 'Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome'. Together they form a unique fingerprint.

Cite this